TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03921684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
Study: NCT00923676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: pill 145 mg, 145 mg/day, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: pills of 10 mg, 10 mg/day, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate + rosuvastatin
Description: fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
Study: NCT05242926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
Study: NCT04299360

Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy device programming
Description: Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
Study: NCT03949686

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution
Description: 0.5 ml/kg saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg %0.25 bupivacaine
Study: NCT03034915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg via ELLIPTA
Description: ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 mcg via ELLIPTA
Description: The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mcg via DISKUS
Description: The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via ELLIPTA
Description: Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via DISKUS
Description: Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via DISKUS
Description: Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Study: NCT03369587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwriting Practice
Description: Self-directed home handwriting practice daily for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handwriting Practice
Description: Self-directed home handwriting practice daily for 6 weeks
Study: NCT01228851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Group balance training sessions three times a week for 8 weeks
Study: NCT01982643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone plus bupropion
Description: Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
Study: NCT03898986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV4)
Description: LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV4)
Description: LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV4)
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV4)
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
Study: NCT01168011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
Study: NCT03321539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT+GP
Description: Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCRT+PF
Description: Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
Study: NCT05097573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
Study: NCT00944801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicine
Description: In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
Study: NCT04333069

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: cataract surgery in form of phaco emulsification or irrigation aspiration
Study: NCT04604054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulated Factor
Description: GCSF was intrauterine injected once at ovum pick up day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropins
Description: 500 IU of HCG was injected intrauterine once at ovum pick up day
Study: NCT02888431

Intervention type: DEVICE
Intervention: bedside point-of-care device
Description: A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.

Intervention type: DEVICE
Intervention: bedside point-of-care device
Description: A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
Study: NCT05098340

Intervention type: GENETIC
Intervention: Quantitative Real-time polymerase chain reaction
Description: Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).

Intervention type: GENETIC
Intervention: Quantitative Real-time polymerase chain reaction
Description: Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
Study: NCT02534441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin patch test
Study: NCT02678104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth removal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth wash
Description: Chlorhexidine mouth wash

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-alveolar application of Manuka Honey
Description: Intra-alveolar application of Manuka Honey directly after extraction.
Study: NCT01947179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Risk Reduction
Description: Involves psychoeducation and interoceptive exposure exercises
Study: NCT01064024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine Hydrochloride
Description: Tablets, 200 mg, every 8 hours for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, every 8 hours for 48 hours
Study: NCT01652248

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac resynchronisation therapy
Description: Upgrade to CRT at the time of generator replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronisation therapy
Description: Upgrade to CRT at the time of generator replacement
Study: NCT01239186

Intervention type: OTHER
Intervention: methylation analyses on spermatozoa from infertile men
Description: microarray analysis(www.EPIGENOMICS.com)
Study: NCT02446730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BES (biodegradable polymer biolimus-eluting stent)
Description: BES implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BES (biodegradable polymer biolimus-eluting stent)
Description: BES implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT04601142

Intervention type: DRUG
Intervention: Methylprednisolone
Description: methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ

Intervention type: DRUG
Intervention: Methylprednisolone
Description: methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
Study: NCT00294008

Intervention type: DRUG
Intervention: Risperdal Consta
Description: flexible dosage for 24 months
Study: NCT01094002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Description: Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities.
Study: NCT02383784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High GI diet
Description: High glycemic index diet
Study: NCT00674102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Study: NCT00649584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35
Description: IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV; 1000 mg/m2 weekly 3 out of 4 weeks
Study: NCT03090152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular injection (Deep injection)
Description: Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular injection (Deep injection)
Description: Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular injection (Superficial injection)
Description: Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular injection (Superficial injection)
Description: Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: EPCA: Bupivacaine 0.06%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: EPCA: Bupivacaine 0.06%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: EPCA: Saline.
Study: NCT00853853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EnSeal Device
Description: Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ferguson Hemorrhoidectomy technique
Description: The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
Study: NCT04701554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong program
Description: The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information on healthy lifestyles, physical exercise and dietary recommendations.
Description: The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
Study: NCT02048007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Biannual mass oral azithromycin to children

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biannual mass oral placebo to children
Study: NCT03283241

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Zolidd One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zolidd One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.
Study: NCT03637348

Intervention type: DEVICE
Group type: OTHER
Intervention: TrueTear
Description: Ues of TrueTear neurostimulator
Study: NCT00629928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg oral capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral capsule daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02378480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Injection for IV dosing; Tablets for oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Infusion solution for IV dosing; Tablets for oral dosing
Study: NCT03205267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosulif
Description: Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
Study: NCT01230060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista
Description: One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
Study: NCT03855904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-325
Description: TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TC-325
Description: TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
Study: NCT05787730

Intervention type: DEVICE
Group type: OTHER
Intervention: Transobturator tape
Study: NCT04201327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Jumpstart
Description: PrEP focused intervention to improve PrEP related health outcomes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Jumpstart
Description: PrEP focused intervention to improve PrEP related health outcomes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Jumpstart
Description: PrEP focused intervention to improve PrEP related health outcomes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Jumpstart
Description: PrEP focused intervention to improve PrEP related health outcomes
Study: NCT02834182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRMf

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IRMf

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini International Neuropsychiatric Interview

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mini International Neuropsychiatric Interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive And Negative Syndrom Scale

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive And Negative Syndrom Scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Mania Rating Scale

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Young Mania Rating Scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Scale

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton Depression Scale
Study: NCT02331043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol ester

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04354610

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological samples specific to research
Description: Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical examination
Description: Clinical examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone follow-up
Description: Telephone follow-up at 3 months after discharge from hospital